Integral PET opens new center

AuntMinnie.com staff writers

Aug 13, 2003

PET services provider Integral PET Associates has opened a PET center in Philadelphia. The New York City-based firm will be providing PET imaging services at the PennPET Center at Pennsylvania Hospital.

By AuntMinnie.com staff writers
August 14, 2003
Related Reading

Integral PET pens Pennsylvania partnership, April 30, 2001

Copyright © 2003 AuntMinnie.com

A 70-year-old female patient with chronic low back pain. History of radicular syndrome which led to targeted nerve block with positive effect. However, lower back pain persisted. FDG-PET/MRI showed increased FDG uptake in a disc herniation at L5-S1 (SUVmax 1.6) convincing the treating physician to proceed to discectomy. After discectomy, the patient is now mostly pain free.

ISMRM: PET/MRI-guided treatment reduces low back pain

May 15, 2026

Molecular Imaging News Platform: trends, insights, professional views.

Molecular Imaging News Platform: trends, insights, professional views.

April 14, 2026

Bayer w6 My4 Ipr De

Bayer issues positive report for cardiac amyloidosis radiotracer

May 7, 2026

PSMA-PET linked to higher use of systemic therapies

May 7, 2026

ISMRM: PET/MRI-guided treatment reduces low back pain

This study is the first to acquire follow-up FDG-PET/MRI scans after treatment to assess the correlation between clinical outcome and FDG uptake.

May 15, 2026

A 70-year-old female patient with chronic low back pain. History of radicular syndrome which led to targeted nerve block with positive effect. However, lower back pain persisted. FDG-PET/MRI showed increased FDG uptake in a disc herniation at L5-S1 (SUVmax 1.6) convincing the treating physician to proceed to discectomy. After discectomy, the patient is now mostly pain free.

SNMMI highlights new radiopharmaceutical therapy

By AuntMinnie.com staff writers

Mice bearing PDAC xenografts received lutetium-177 (Lu-177) AKIR001, a radiopharmaceutical that targets CD44v6.

May 13, 2026

Biodistribution of Lu-177 AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with Lu-177 AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 hours (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 hours postinjection. GI = gastrointestinal.

Bayer issues positive report for cardiac amyloidosis radiotracer

By AuntMinnie.com staff writers

I-124 evuzamitide met its primary endpoints, according to Bayer.

May 7, 2026

Bayer w6 My4 Ipr De

PSMA-PET linked to higher use of systemic therapies

ARPI therapy was initiated in 15.6% of PSMA-PET patients versus 7.7% of bone scan patients.

May 7, 2026

Eden Radioisotopes files NRC permit for isotope production complex

By AuntMinnie.com staff writers

The company said the facility is designed to produce up to 50% of global demand for molybdenum-99 (Mo-99).

May 6, 2026

Chinese scientists develop wearable brain PET system

The system could offer new opportunities for brain PET imaging beyond the constraints of conventional static systems.

May 1, 2026

(A) System comprises detectors and silicon photomultipliers with custom Hoffman brain phantom. (B) Seated-position scanning. (C) Backpack system permitting data collection in ambulatory states. (D) Workstation scenario demonstrating natural seated use.

NET tracers first widened, then closed imaging access gap

Ga-68 DOTATATE/DOTATOC captured 33.8% market share in its 2017 debut and reached 90.9% by 2020.

April 30, 2026

Adobe Stock 107601498

Serac highlights study on 99mTc-maraciclatide for endometriosis care

By AuntMinnie.com staff writers

Serac Healthcare is highlighting success from a study that evaluated the company's gamma-emitting radiotracer, 99mTc-maraciclatide.

April 30, 2026

Endometriosis 3 D Illustration 400

Lu-177 PSMA-SPECT/CT predicts survival in mCRPC

Lu-177 PSMA-617 SPECT/CT total tumor volume complete response at six weeks associated with overall survival.

April 29, 2026

Quantification of total tumor volume (TTV) at lutetium-177 prostate-specific membrane antigen (PSMA)–617 SPECT/CT shows heterogeneous TTV responses between dose 1 (Cycle #1) and dose 2 (Cycle #2) in participants with metastatic castration-resistant prostate cancer. Posttherapy coronal attenuation-corrected noncontrast SPECT/CT maximum intensity projection images demonstrate (A) near-complete response in a 76-year-old man, (B) complete response in an 83-year-old man, (C) partial TTV reduction (not complete response) in a 69-year-old man, and (D) TTV increase (i.e. progressive disease) in a 74-year-old man. Blue-shaded regions represent semiautomatically segmented PSMA-avid tumor volume, with associated TTV values given at the bottom of each panel. The gradient bar shows standardized uptake value (SUV) from 0 to 5.

PET improves treatment planning for pituitary tumors

Ga-68 DOTATATE PET altered radiation treatment volumes by nearly 20% compared with MRI alone.

April 28, 2026

A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).

PharmaLogic opens PET radiopharmaceutical facility in Atlanta

By AuntMinnie.com staff writers

PharmaLogic Holdings has opened a PET radiopharmaceutical manufacturing facility in Atlanta.

April 28, 2026

Georgia Atlanta Map Pin

C-Ray Therapeutics wins FDA active status for Cu-64 drug master file

By AuntMinnie.com staff writers

C-Ray Therapeutics has received active status from the FDA for its Type II Drug Master File for Cu-64 chloride for radiolabeling.

April 28, 2026

Page 1 of 626